Fresenius Medical Care AG & Co. KGaA·Healthcare

Hemodiafiltration (HDF) research reinforces Fresenius Medical Care's continued leadership in advancing evidence-based dialysis care and treatment personalization New research focuses on applying real-world evidence, patient-centered outcomes and artificial intelligence across dialysis modalities and continuity of kidney care A preview of kinexus, a unified digital platform intended to support home dialysis programs by connecting therapy management and care workflows BAD HOMBURG, Germany, May 27, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with kidney diseases, presents new research highlighting ongoing innovation at the European Renal Association (ERA) Congress 2026, June 3-6 in Glasgow, Scotland, and virtually. The Company highlights advancements including new hemodiafiltration research that reaffirm its leadership in evidence based and personalized dialysis care, real-world evidence to strengthen patient centered outcomes across dialysis modalities, and the application of artificial intelligence (AI) to improve patient outcomes.

Total volume of the share buyback is around EUR 1 billion over 12 months Share buyback expected to begin in the near future BAD HOMBURG, Germany, May 26, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, intends to execute a new share buyback program with a total volume of around EUR 1 billion. The program shall be executed in tranches over a period of 12 months from its start.

Toronto, Ontario--(Newsfile Corp. - May 21, 2026) - Dean Hanisch, Chief Executive Officer, Focus Graphite Inc. ("Focus Graphite Advanced Materials" or the "Company") (TSXV: FMS), shares the Company's story in an interview with TMX Group. Cannot view this video?

Fresenius Medical Care Annual General Meeting: Strengthening performance and advancing innovation in kidney care PR Newswire

Shareholders approve proposed dividend of EUR 1.49 per share FME Reignite strategy launched in 2025 successfully drives the next phase of value creation 5008X CAREsystem introduced in U.S. clinics; full U.S. commercial launch underway in 2026 EUR 1 billion share buyback program successfully completed, and a new authorization granted to support the Company's capital allocation framework which includes share buyback programs BAD HOMBURG, Germany, May 21, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has completed a milestone year marked by significant improvements in profitability. Over the past three years, the Company has successfully delivered on its mid‑term financial and strategic targets set for 2025.

Fresenius Medical Care Reappoints Chief Financial Officer Martin Fischer PR Newswire BAD HOMBURG, Germany, May 2
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Healthcare
Medical - Care Facilities
112,035
1996-09-17
0.82